These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. Gilday E; Nasrallah HA Rev Recent Clin Trials; 2012 Feb; 7(1):2-9. PubMed ID: 22023179 [TBL] [Abstract][Full Text] [Related]
7. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242 [TBL] [Abstract][Full Text] [Related]
8. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Nasrallah HA; Gopal S; Gassmann-Mayer C; Quiroz JA; Lim P; Eerdekens M; Yuen E; Hough D Neuropsychopharmacology; 2010 Sep; 35(10):2072-82. PubMed ID: 20555312 [TBL] [Abstract][Full Text] [Related]
9. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. Lafeuille MH; Grittner AM; Fortier J; Muser E; Fasteneau J; Duh MS; Lefebvre P Am J Health Syst Pharm; 2015 Mar; 72(5):378-89. PubMed ID: 25694413 [TBL] [Abstract][Full Text] [Related]
11. Maintenance treatment with long-acting injectable antipsychotics: comparing old with new. Goff DC JAMA; 2014 May; 311(19):1973-4. PubMed ID: 24846032 [No Abstract] [Full Text] [Related]
12. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Sliwa JK; Bossie CA; Ma YW; Alphs L Schizophr Res; 2011 Oct; 132(1):28-34. PubMed ID: 21775106 [TBL] [Abstract][Full Text] [Related]
13. Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone. Perry R; Wolberg J; DiCrescento S Am J Health Syst Pharm; 2012 Jan; 69(1):40-3. PubMed ID: 22180550 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Gopal S; Hough DW; Xu H; Lull JM; Gassmann-Mayer C; Remmerie BM; Eerdekens MH; Brown DW Int Clin Psychopharmacol; 2010 Sep; 25(5):247-56. PubMed ID: 20389255 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial. Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612 [TBL] [Abstract][Full Text] [Related]
16. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia. Alphs L; Mao L; Rodriguez SC; Hulihan J; Starr HL J Clin Psychiatry; 2014 Dec; 75(12):1388-93. PubMed ID: 25375367 [TBL] [Abstract][Full Text] [Related]
17. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. Coppola D; Liu Y; Gopal S; Remmerie B; Samtani MN; Hough DW; Nuamah I; Sulaiman A; Pandina G BMC Psychiatry; 2012 Mar; 12():26. PubMed ID: 22455454 [TBL] [Abstract][Full Text] [Related]